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Summary
Invasive lobular carcinoma (ILC) is the second most prevalent histologic subtype of invasive 
breast cancer. Here, we comprehensively profiled 817 breast tumors, including 127 ILC, 490 
ductal (IDC), and 88 mixed IDC/ILC. Besides E-cadherin loss, the best known ILC genetic 
hallmark, we identified mutations targeting PTEN, TBX3 and FOXA1 as ILC enriched features. 
PTEN loss associated with increased AKT phosphorylation, which was highest in ILC among all 
breast cancer subtypes. Spatially clustered FOXA1 mutations correlated with increased FOXA1 
expression and activity. Conversely, GATA3 mutations and high expression characterized 
Luminal A IDC, suggesting differential modulation of ER activity in ILC and IDC. Proliferation 
and immune-related signatures determined three ILC transcriptional subtypes associated with 
survival differences. Mixed IDC/ILC cases were molecularly classified as ILC-like and IDC-like 
revealing no true hybrid features. This multidimensional molecular atlas sheds new light on the 
genetic bases of ILC and provides potential clinical options.
INTRODUCTION
Invasive lobular carcinoma (ILC) is the second most frequently diagnosed histologic 
subtype of invasive breast cancer, constituting ~10–15% of all cases. The classical form 
(Foote and Stewart, 1946) is characterized by small discohesive neoplastic cells invading the 
stroma in a single-file pattern. The discohesive phenotype is due to dysregulation of cell–
cell adhesion, primarily driven by lack of E-cadherin (CDH1) protein expression observed in 
~90% of ILCs (McCart Reed et al., 2015; Morrogh et al., 2012). This feature is the ILC 
hallmark and immunohistochemistry (IHC) scoring for CDH1 expression is often used to 
discriminate between lesions with borderline ductal versus lobular histological features. ILC 
variants have also been described, yet all display loss of E-cadherin expression (Dabbs et al., 
2013).
Classic ILCs are typically of low histologic grade and low to intermediate mitotic index. 
They express estrogen and progesterone receptors (ER and PR) and rarely show HER2 
protein overexpression or amplification. These features are generally associated with a good 
prognosis, yet some studies suggest that long-term outcomes of ILC are inferior to stage-
matched invasive ductal carcinoma (IDC) (Pestalozzi et al., 2008). Importantly, ILC 
infiltrative growth pattern complicates both physical exam and mammographic findings and 
its patterns of metastatic spread often differ from those of IDC (Arpino et al., 2004).
To date, genomic studies of ILC have provided limited insight into the biologic 
underpinnings of this disease, mostly focusing on mRNA expression and DNA copy number 
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analysis (McCart Reed et al., 2015). The first TCGA breast cancer study (Cancer Genome 
Atlas, 2012) reported on 466 breast tumors assayed on six different technology platforms. 
ILC was represented by only 36 samples and, no lobular-specific features were noted 
besides mutations and decreased mRNA and protein expression of CDH1. Here, we 
analyzed nearly twice as many breast tumors from TCGA (n=817), including 127 ILC. This 
study identified multiple genomic alterations that discriminate between ILC and IDC 
demonstrating at the molecular level that ILC is a distinct breast cancer subtype and 
providing new insight into ILC tumor biology and therapeutic options.
RESULTS
Genetic determinants of Invasive Lobular Cancer (ILC)
A total of 817 breast tumor samples were profiled with 5 different platforms as previously 
described (Cancer Genome Atlas Research, 2014) and 633 cases were also profiled by 
reverse-phase protein array (RPPA). A pathology committee reviewed and classified all 
tumors into 490 IDC, 127 ILC, 88 cases with mixed IDC and ILC features, and 112 with 
other histologies (Table S1). As expected, lobular tumors were predominantly classified as 
Luminal A (LumA) (Figure 1A) and being typically ER+ tumors characterized by low levels 
of proliferation markers (Table S1). ER status was clinically determined by 
immunohistochemistry on 120 of 127 ILC cases, with 94% (n=113) scoring positively
Within 127 ILC, we identified 8173 total coding mutations, integrating information from 
both DNA and RNA sequencing (Wilkerson et al., 2014). Recurrently mutated genes in ILC 
were identified by MutSigCV2 (Lawrence et al., 2013) and included many genes previously 
implicated in breast cancer (Figure 1B, Table 1) (Cancer Genome Atlas, 2012). Similarly, 
recurrent copy number alterations in ILC estimated by GISTIC (Mermel et al., 2011) 
recapitulated known breast cancer gains and losses, in particular those observed in ER+/
Luminal tumors (Figure S1A). However, the frequency of these alterations (both mutations 
and copy number changes) often differed significantly between IDC and ILC.
To investigate these differences, we identified recurrent alterations across all 817 samples 
and separately in ILC and IDC PAM50 subtypes (Luminal A, n=201, Luminal B, n=122, 
HER2-enriched, n=51, and Basal-like, n=107). In total, we identified 178 events, including 
68 mutated genes, 47 regions of gain and 63 regions of loss (Table 1 and Table S2). Several 
of these had different incidence in ILC and in IDC (Figure 1C, Table S3). ILC cases were 
significantly enriched for CDH1 mutations, (63% in ILC vs. 2% in IDC, q=3.94E-53), most 
of them truncating, and mutations affecting TBX3 (9% vs. 2%, q=0.003), RUNX1 (10% vs. 
3%, q=0.008), PIK3CA (48% vs. 33%, q=0.02) and FOXA1 (7% vs. 2%, q=0.08). By 
contrast, alterations typically observed in ER−/Basal-like tumors were less frequent in ILC 
including TP53 mutations (8% in ILC vs. 44% in IDC, q=1.9E-14) and focal amplification 
of MYC (6% vs. 27%, q=7.42E-7) and CCNE1 (0% vs. 7%, q=0.01). These results partly 
reflect genetic differences between ER+/Luminal and ER−/Basal-like breast cancer, given 
that ILC tumors were predominantly LumA. Nonetheless, unexpected differences did 
emerge including a lower incidence of GATA3 mutations in ILC compared to IDC (5% in 
ILC vs. 13% in IDC, q=0.03) (Figure 1C).
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To better identify ILC discriminatory features, we limited our analyses to LumA samples, 
representing 41% of IDC (n=201) and 83% of ILC (n=106) (Figure 1D). This analysis 
confirmed a high incidence of CDH1 (q=1.4E-30), TBX3 (q=0.05) and FOXA1 (q=0.065) 
mutations in ILC, while the frequency of RUNX1 and PIK3CA mutations was no longer 
significantly different. GATA3 mutations (5% ILC vs. 20% IDC, q=0.003) were the second 
most discriminant event after CDH1 mutations, mostly affecting IDC tumors. Interestingly, 
both FOXA1 and GATA3 are key regulators of ER activity (Liu et al., 2014), suggesting IDC 
and ILC may preferentially rely on different mechanisms to mediate the ER transcriptional 
program. Finally, homozygous losses of the PTEN locus (10q23) were more frequent in ILC 
(q=0.035) as were PTEN mutations (8% vs. 3%). Collectively, PTEN inactivating alterations 
were identified in 14% of LumA ILC versus 3% of LumA IDC (p=9E-4), making this the 
third most discriminant feature between LumA IDC and LumA ILC (Figure 1D).
E-cadherin loss in invasive lobular carcinoma
Loss of the epithelial specific cell-cell adhesion molecule E-cadherin (CDH1) is the key 
hallmark of ILC (Dabbs et al., 2013; Moll et al., 1993). CDH1 loss is believed to confer the 
highly discohesive morphology characteristic of this tumor subtype and is often associated 
with tumor invasion and metastasis in other tumor types, including diffuse gastric cancer 
(Brinck et al., 2004; Cancer Genome Atlas Research, 2014; Richards et al., 1999). Loss-of-
function mutations targeting CDH1 are present in 50–60% of ILC and are believed to be an 
early event often observed in matching lobular carcinoma in situ (LCIS) (McCart Reed et 
al., 2015). CDH1 mutations typically occur in combination with chromosome 16q loss, 
where CDH1 is located, thus inducing complete loss of the protein.
We identified 108 mutations in the coding sequence of CDH1 in 107/817 patients (63%); 80 
of these occurred in ILC cases. These mutations were rather uniformly distributed along the 
coding sequence and 83% of them were predicted to be truncating (Figure 2A). CDH1 
mutations almost invariably co-occurred with heterozygous loss of 16q (affecting 89% of 
ILC cases), and were associated with down-regulation of both CDH1 transcript and protein 
levels (Figures 2B and S2A). By combining somatic mutations, copy number losses, and 
mRNA and low protein expression (the latter when available), we identified E-cadherin 
alterations in 120/127 (95%) cases with DNA and RNA data, and in all 79 cases with DNA, 
RNA, and protein data (Figure S2A–C).
Previous studies reported sporadic cases of multiple cancer types with high DNA 
methylation levels at the CDH1 promoter, suggesting epigenetic silencing as an alternative 
mechanism for down-regulation of CDH1 (Graff et al., 1997; Richards et al., 1999; Sarrio et 
al., 2003; Zou et al., 2009). We analyzed the DNA methylation levels in breast tumors at 
CpG sites spanning from upstream of the CDH1 promoter, across the promoter CpG island, 
and extending into the first intron (Figure S2D). Despite four of these probes matching DNA 
positions previously reported as methylated in ILC (Graff et al., 1997; Sarrio et al., 2003; 
Zou et al., 2009), we did not detect significant DNA hyper-methylation at these probes 
(Figure S2E), nor in any of the other CDH1 associated probes analyzed (Figures 2B and 
S2F–G). Moderately increased methylation was observed in a few cases near exon 2, 
however DNA methylation at this site correlated with lower tumor purity and increased 
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leukocyte infiltration, and indeed it mimicked methylation levels at this CpG site in normal 
leukocytes (Figure S2F–G). Infinium DNA methylation results were validated by whole 
genome bisulfite sequencing in 5 samples (Figure S2H). Altogether these data confirm that 
CDH1 expression was substantially lower in ILC than in IDC, and that this expression 
difference did not appear associated with DNA methylation at the CDH1 promoter. Our 
results on 817 invasive breast tumors thus confirmed Ecadherin loss as ILC defining 
molecular feature, but do not support the reported occurrence of CDH1 epigenetic silencing 
in invasive breast cancer. The discrepancy with prior literature may be attributable in part to 
the reliance on highly sensitive, but non-quantitative methylation-specific PCR assays in 
past studies (Herman et al., 1996) and will require further investigation.
FOXA1 mutations in breast cancer
FOXA1 is a key ER transcriptional modulator (Carroll et al., 2005; Hurtado et al., 2011) 
coordinating ER DNA binding within a large protein complex by modifying chromatin 
accessibility and mediating long-range DNA interactions (Liu et al., 2014). High FOXA1 
expression has been previously reported in breast and prostate cancer (Habashy et al., 2008; 
Sahu et al., 2011) and somatic mutations in the FOXA1 gene have been reported in these 
tumor types in about 3–4% of the cases (Barbieri et al., 2012; Cancer Genome Atlas, 2012; 
Robinson et al., 2015).
Here, we observed a total of 33 FOXA1 mutations in 30/817 (3.7%) tumors (Figure 3A) and 
the large sample set allowed us to identify regional hotspots in the FOXA1 mutation 
distribution. Mutations clustered in the fork-head DNA binding (FK) and C-terminus 
transactivation domains (Figure 3A). A similar mutational pattern was observed by 
combining multiple prostate cancer sequencing studies (Baca et al., 2013; Barbieri et al., 
2012; Grasso et al., 2012; Robinson et al., 2015) (Figure S3A), and confirmed by the TCGA 
prostate cancer project (TCGA 2015, in press). Thus, regional FOXA1 mutation hotspots are 
selectively altered in a tissue-independent fashion.
Eleven FOXA1 mutations were observed in 9/127 (7%) ILC cases. All FOXA1 mutations in 
ILC were in the FK domain, whereas mutations in IDC (n=11) were observed both in FK 
(n=6) and other structural elements (n=5), without a specific preference. The FK domain 
includes three α-helices (H1, H2, H3), three β-strands (S1, S2, S3) and two loops, typically 
referred to as “wings” (W1, W2) (Figures 3B and S3B). FOXA1 mutations in FK clustered 
prevalently in the W2 loop. Notable exceptions were recurrently mutated residues I176 
(n=4) and D226 (n=3). These residues are far from W2 in sequence space and located in 
different secondary structure elements; however they are close (within 5 to 10 Angstroms) to 
residues in W2 in the three-dimensional (3D) space (Figures 3C–D and S3C). In total 22 out 
of 25 FK-mutations in our dataset fall into a restricted 3D space or “mutation structural 
hotspot” (MSH) (Figure 3D) indicating a selective pressure for targeting protein interactions 
and functions mediated by this region. Notably, 8/127 ILC cases have FOXA1 mutations 
within this MSH compared to 4/490 IDC cases (p=6E-4), further supporting FOXA1 selected 
mutations as an ILC feature.
FOXA1 DNA binding occurs mostly through helix H3, that recognizes the binding motif, 
and is stabilized by interactions mediated by its “wings” (Cirillo and Zaret, 2007; Gajiwala 
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and Burley, 2000; Kohler and Cirillo, 2010). Only a few residues predicted or 
experimentally shown to interact with the DNA were mutated (Figure 3B–E) suggesting that 
these events are unlikely to affect FOXA1 DNA binding. FOXA1 is a pioneer factor that 
binds condensed chromatin and triggers DNA demethylation of its binding sites, making 
them accessible to transcription factors such as ER (Cirillo et al., 2002; Serandour et al., 
2011). FOXA1 activity can therefore be estimated by the methylation status of these sites 
where occupied FOXA1 DNA binding sites tend to be demethylated. We analyzed DNA 
methylation levels of the 3976 most variable methylation probes mapping to FOXA1 
binding sites (Table S3) and methylated in normal samples (Ross-Innes et al., 2012; Wang et 
al., 2012). DNA methylation of these sites was substantially lower when FOXA1 and ESR1 
were highly expressed, while it remained high in FOXA1-negative cases and adjacent 
normal tissue (Figure 3F). Inverse correlation with FOXA1 expression (Pearson’s coefficient 
ρ=−0.54) was specifically observed for DNA methylation at FOXA1 binding sites. Indeed, 
no correlation was found with methylation at 2000 most variable probes with the same 
methylation level in normal samples as FOXA1 binding sites (ρ=0.07) (Figure 3F). These 
data support the hypothesis that FOXA1 mRNA expression correlates with its activity. 
FOXA1 mutations were positively associated with its mRNA expression (p=0.002) and 
maintained a similar anti-correlation with DNA methylation at FOXA1 binding sites (Figure 
3F). Finally, by examining mRNA expression of FOXA1 targets, defined as genes with a 
FOXA1 binding motif in the promoter or matching the genomic loci covered by the 3976 
methylation probes we analyzed (Table S3), no significant differences were identified and 
only a few genes showed moderate expression changes (Table S4). These data collectively 
indicate that FOXA1 mutations do not abolish protein function and, in fact, they may 
activate alternative mechanisms to affect ER transcriptional programs.
Differential expression analyses between FOXA1 mutant and wild type cases within distinct 
subsets of samples found consistent up-regulation of neuroendocrine secretory proteins 
SCG1 (CHGB) and SCG2, chemokine-like factor CMTM8, neuroendocrine tumor associated 
transcription factor NKX2-2 and Kallikrein serine proteases KLK12, KLK13, and KLK14 
(Figure S3D and Table S5). While the relatively low number of FOXA1 mutations and 
breast cancer heterogeneity prevented the identification of strong transcriptional signals 
associated with FOXA1 mutations, several upregulated targets in FOXA1 mutant cases with 
part of them consistently found as significant suggests these lesions might drive novel 
binding events.
Interestingly, while ILC cases were enriched for FOXA1 mutations and in particular for 
those targeting the FK domain, ILC showed significantly fewer GATA3 mutations, another 
key ER modulator. Mutations in GATA3 were more frequent in LumA IDC (Figure 1D) and 
mutually exclusive with FOXA1 events. Moreover, LumA ILC tumors show lower GATA3 
mRNA (p=0.007) and protein (p=2E-4) levels than LumA IDC (Figure S3E–F). Taken 
together, the differential expression patterns and enrichment for hotspot mutations of 
GATA3 in IDC and of FOXA1 in ILC, suggest a preferential requirement for distinct ER 
modulators in ILC and IDC.
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Akt signaling is strongly activated in ILC
PTEN inactivation emerged as a discriminant feature between Luminal A ILC and Luminal 
A IDC. PTEN genetic alterations across all ILC cases included homozygous deletions (6%) 
and somatic mutations (7%), and were largely mutually exclusive with PIK3CA mutations 
(48%) (Figure S4A).
Unbiased differential protein expression analysis (Table S6) based on RPPA data revealed 
significant lower PTEN protein expression (p=4E-4) in LumA ILC compared to LumA IDC 
(Figure 4A). Consistent with PTEN function as a negative regulator of Akt activity (Cantley 
and Neel, 1999; Song et al., 2012), ILC tumors also showed significantly increased Akt 
phosphorylation at both S473 (p=0.004) and T308 (p=7E-5) (Figure 4A). Upstream of the 
Akt pathway, we found significant up-regulation of total EGFR (p=1E-4) and phospho-
EGFR at Y1068 (p=0.005) and Y1173 (p=0.007), as well as phospho-STAT3 at Y705 
(p=7E-4), supporting up-regulation of signaling axes converging on Akt activation (Wu et 
al., 2013). We also identified increased phospho-p27 at T157 (p=0.002), an Akt substrate, 
and phospho-p70S6 kinase at T389 (p=1E-4), a direct mTOR target. Notably, ILC phospho-
Akt levels were comparable with those typically observed in the more aggressive HER2+ 
and ER−/Basal-like breast tumors (Figure S4B), which have uniformly high levels of 
PI3K/Akt signaling (Cancer Genome Atlas, 2012). Consistent with these results, we found 
significant up-regulation of a PI3K/Akt pathway-specific protein and phospho-protein 
expression signature (Akbani et al., 2014) in LumA ILC compared to LumA IDC (Figure 
4B, Tables S1 and S6). Based on this signature, we found nearly equivalent levels of 
PI3K/Akt signaling in LumA ILC and Basal-like and HER2+ IDC (Figure S4C). Finally, 
PARADIGM analyses (Vaske et al., 2010) showed increased activation of Akt signaling in 
LumA ILC relative to LumA IDC (Figure 4D).
PTEN protein loss and increased Akt phosphorylation were observed in association with 
PTEN genetic alterations, as well as in multiple ILC PTEN wild-type cases indicating that 
additional mechanisms contribute to the activation of the pathway. While PIK3CA mutations 
were frequent in LumA ILC tumors, these mutations were not associated with increased 
levels of phospho-Akt or pathway activity in our dataset. Using MEMo (Ciriello et al., 
2012), we highlighted multiple genetic alterations converging on Akt/mTOR signaling in 
45% of the samples (Figure S4D, Table S7). Among these, alterations acting upstream of 
Akt were identified in 40% of ILC cases and were associated with increased Akt 
phosphorylation and PI3K/Akt score (Figure 4E) providing an apparent molecular 
explanation for Akt activation in these samples. Interestingly, these events included ERBB2 
amplification and mutations (Figure 4E), both of which have been identified in relapsed ILC 
(Ross et al., 2013).
ILC mRNA subtypes
Using mRNA-seq expression data from LumA ILC samples (n=106), we identified 3 ILC 
subtypes termed reactive-like, immune-related, and proliferative (Figure S5A–I, Table S8). 
We then used a 3-class ILC subtype classifier (60 genes, Table S13) to score all ILC 
samples in the TCGA (n=127) (Figure 5A) and METABRIC (Curtis et al., 2012) datasets 
(Table S12 to Table S8). Our analyses identified many significant genomic features that 
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distinguished each ILC subtype at the mRNA and protein/phospho-protein level; but no 
distinguishing somatic mutations or DNA copy number alterations.
Significant Analysis of Microarray (SAM) analysis (Tusher et al., 2001) identified 1277 
genes differentially expressed between ILC subtypes (q=0) (Figure 5A, Table S8). Of these, 
1005 were highly expressed in reactive-like tumors, which had lower tumor purity as 
determined by ABSOLUTE (Carter et al., 2012) (Figures 5A and S5P), and included genes 
consistent with epithelial and stromal-associated signaling including keratin, kallikrein, and 
claudin genes as well as the oncogenes EGFR, MET, PDGFRA and KIT (Table S14 to Table 
S8). The remaining 272 genes were highly expressed in immune-related tumors and include 
modulators of immunogenic signaling such as interleukins (IL), chemokine receptors and 
ligands, major histocompatibility complex, and tumor necrosis factors, as well as IDO1 and 
IFNG (Table S14 to Table S6). Interestingly, immune activity in this subset of tumors 
appears to be predominantly associated with macrophage-associated signaling as increased 
levels of CD68 (p<0.05), Macrophage-associated Colony Stimulating Factor (MacCSF), 
Macrophage-associated TH1 (MacTH1), and T-cell Receptor (TCR) gene expression 
signatures (Iglesia et al., 2014) were observed in both the TCGA (Figure 5A) and 
METABRIC (Figure S5J–K) datasets. Finally, proliferative tumors were defined by low 
expression of each of these 1277 genes (Figure 5A). Intriguingly, in each dataset (Figures 5 
and S5K) proliferative tumors had higher levels of proliferation relative to reactive-like 
tumors (TCGA: p=3.3E-09; METABRIC: p=0.018) and slightly higher or equivalent levels 
compared to immune-related ones (TGCA: p=0.29; METABRIC: p=0.008). Regardless of 
ILC subtype, ILC tumor proliferation was generally lower than all IDC subtypes (Figure 
S5L–M).
With respect to previously reported RPPA-based subtypes (Reactive or non-Reactive), 
reactive-like ILC largely, but not entirely, comprised tumors classified as Reactive (Figure 
5B; p<1E-4), a subgroup characterized by strong microenvironment and/or cancer fibroblast 
signaling (Cancer Genome Atlas, 2012). Examining protein and phospho-protein expression 
differences between ILC subtypes identified many significant features (Table S8 to Table 
S6). Reactive-like tumors had higher levels of c-Kit (p=4E-4), consistent with mRNA 
expression, total (p=0.004) and phosphorylated PKC alpha (S657, p=0.002); beta catenin 
(p=0.012) and E-cadherin (p=0.011), although both beta-catenin and E-cadherin levels are 
significantly lower than in all IDC subtypes. Decreased levels were observed instead for 
p70S6 kinase (p=0.017), Raptor (p=0.027) and eIF4G (p=0.024).
Immune-related tumors had higher levels of immune modulator STAT5 alpha (p=0.019), 
PI3K/Akt targets phospho-PRAS40 (T246, p=0.016) and mTOR (S2448, p=0.019), and total 
(p=0.004) and phospho-MEK1 (S217–S221, p=0.022). Consistent with the mRNA 
proliferation signature, tumors in the proliferative subtype have increased expression of cell 
cycle proteins Cyclin E1 (p=0.036), FoxM1 (p=0.019), PCNA (p=0.019), and propsho-Chk1 
(S345, p=0.038) as well as DNA repair components Rad50 (p=0.007), Rad51 (p=0.007), 
XRCC1 (p=0.028) and BRCA2 (p=0.038). Decreased expression was observed for total 
(p=0.014) and phospho-MAPK (T202-Y204, p=0.038), and phosphorylated MEK1 (S217–
S221, p=0.019), PKC alpha (S657, p=0.006), PKC beta (S660, p=0.037), and Src (Y527, 
p=0.026). Protein pathway signatures (Akbani et al., 2014) recapitulated these findings with 
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proliferative tumors having increased levels of the Cell Cycle (p=0.005) and DNA Damage 
Response (p=0.014) signatures and a lower RAS-MAPK signature (p=0.031) score (Tables 
S1 and S6).
Using an integrative genomics approach, PARADIGM predicted increased activation of the 
TP53, TP63, TP73 TCF/beta-catenin PKC, and JUN/FOS pathways in reactivelike tumors; 
increased activation of immune-modulators IL12, and IL23, IL12R and IL23R, JAK2 and 
TYK2 in immune-related ILCs (Baay et al., 2011; Duvallet et al., 2011; Strobl et al., 2011); 
and decreased activation of each of these pathways along with lower levels of MAPK3, 
RB1, and ERK1 (Figure 5C) in proliferative ILC tumors.
Lastly, we determined that reactive-like ILC patients had a significantly better disease-
specific (DSS) (p=0.038, HR: 0.47) and overall survival (OS) (p=0.023, HR: 0.50) 
compared to proliferative ILC patients in the METABRIC dataset, which has a median 
follow-up of 7.2 years (compared to the TCGA median follow-up of less than 2 years), 
(Figure 5D). Consistent with these results, patients with more proliferative lobular tumors 
(i.e. greater than the median PAM50 proliferation signature score) had worse DSS (p=0.025, 
HR: 2.0) and a tendency towards worse OS (p=0.058, HR: 0.63) compared to patients with a 
lower proliferation score (Figure S5N–O). No significant differences in DSS or OS were 
identified between the immune-related subgroup and either the proliferative or reactive-like 
subgroup. These results are consistent with previous studies reporting that the reactive 
stromal phenotype is associated with a good prognosis in breast cancer while proliferation is 
one of the strongest indicators of worse outcome in luminal/ER+ breast cancers (Ciriello et 
al., 2013b).
Tumors with mixed ILC and IDC histology
Histologically, ~3–6% of breast tumors present both a ductal and a lobular component 
(Figure 6A). Pathologists currently classify these tumors as mixed ductal/lobular breast 
carcinoma or invasive ductal cancers with lobular features (Arps et al., 2013). There are, 
however, no defined criteria or uniform terminology for the classification of mixed tumors 
and as a consequence discordant clinical and molecular features have been reported (Bharat 
et al., 2009). Molecular profiling has the power to provide quantitative endpoints to compare 
the genetics of mixed tumors with those of pure ILC and IDC. In our dataset, 88/817 tumors 
(11%) were classified by as mixed ductal/lobular breast carcinomas. We characterized these 
mixed tumors using multiple computational approaches integrating different data-types thus 
to determine whether they molecularly resembled IDC (IDC-like), ILC (ILC-like), or 
neither.
We first analyzed the transcriptional landscape of mixed tumors using the ISOpure 
algorithm (Quon et al., 2013), which deconvolves the transcriptional signal of each queried 
tumor to estimate how much of it can be explained by one or more reference populations 
and how much is unique. Interestingly, mRNA expression profiles of all mixed cases could 
almost completely be explained by either IDC or ILC reference populations, suggesting that 
these tumors separate into IDC-like and ILC-like cases and do not represent a molecularly 
distinct subtype (Figure S6A). Based on these analyses, 32/88 mixed cases received an ILC-
score greater than the IDC-score, and were therefore classified as ILC-like (Figure 6B).
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We next evaluated the resemblance of mixed tumors to IDC and ILC based on the previously 
determined selected set of copy number alterations (CNAs) and mutations (Table S2). Mixed 
tumors were enriched for IDC recurrent CNAs and mutations when compared to ILC, and 
vice versa (Figure S6B), indicating ILC and IDC genetic alterations were both present in 
these tumors, either simultaneously or in separate IDC-like and ILC-like subgroups. We 
then compared each mixed tumor to ILC and IDC based on their genomic features, by 
adapting the OncoSign algorithm (Ciriello et al., 2013a). This approach identified 19 ILC-
like mixed samples characterized by ILC genetic features (Figures 6B and S6D). All CDH1-
mutated mixed cases were classified as ILC-like, indicating CDH1 status as a dominant 
feature in this analysis. A few CDH1 wild-type mixed cases were also classified as ILC-like 
and characterized by ILC-enriched events such as mutations in RUNX1 (3/4 mutated cases), 
TBX3 (2/4) and FOXA1 (2/6). ILC-enriched alterations did not co-occur with IDC-enriched 
ones, further indicating that mixed tumors can be categorized into ILC-like or IDC-like 
subgroups and do not constitute a molecularly distinct subtype.
Finally, we combined 428 CNA, including focal and arm-level alterations, 409 gene 
expression modules (Fan et al., 2011; Gatza et al., 2014) and somatic mutations for 128 
genes mutated in more than 3% of the cases into a single ElasticNet classifier (Zou and 
Hastie, 2005). This integrated ElasticNet predictor identified 27/88 mixed tumors as ILC-
like. These were enriched for the LumA subtype, CDH1 mutations and loss of E-cadherin 
mRNA expression (Figures 6B and S6E).
Overall, these approaches were highly concordant (Figures 6B and S6F) with 24/88 cases 
(18/57 LumA cases) being called ILC-like by at least two approaches, and 64 being called 
IDC-like (Table S1). ILC-like and IDC-like mixed tumors when compared to pure ILC and 
IDC, respectively, do not show significant enrichment for specific genomic alterations, 
being molecularly similar to either one or the other subtype. Our analyses demonstrate that 
mixed histology tumors overwhelmingly tend to resemble either ILC or IDC as opposed to 
representing a third distinct group. Moreover, IDC and ILC discriminant molecular features, 
in particular CDH1 status, could be used to stratify mixed tumors into ILC-like and IDC-like 
tumor subgroups.
Discussion
In this study we provide the most comprehensive molecular portrait to date of ILC. E-
cadherin loss was confirmed the ILC hallmark lesion and we could identify CDH1 loss at 
the DNA, mRNA, and protein level in almost all ILC cases. Moreover, 12/27 CDH1 
mutations in non-ILC cases occurred in mixed tumors strongly resembling ILC at the 
molecular level. Surprisingly, we did not identify DNA hyper-methylation of the CDH1 
promoter in any breast tumor, suggesting that E-cadherin loss is not epigenetically driven. In 
addition, ILC and IDC differed in the FOXA1 and GATA3 mutational spectra, PTEN loss, 
and Akt activation. The lower incidence of GATA3 mutations in ILC and lower GATA3 
mRNA and protein expression suggest that in LumA ILC tumors there is a preferential 
occupancy of ER in FOXA1 bounded sites (Theodorou et al., 2013). Differential ER activity 
is also observed at the protein level where both total ER (p=0.005) and phospho-ER 
(p=2E-05) levels are reduced in LumA ILC vs. LumA IDC. These findings in the context of 
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recent data suggesting an improved response to the aromatase inhibitor letrozole as 
compared to tamoxifen in ILC (Metzger et al., 2012; Sikora et al., 2014) warrants further 
investigation.
The chromatin remodeling factor EP300, also involved in ER modulation, is able to directly 
acetylate FOXA1, and EP300 driven acetylation prevents FOXA1 DNA binding, but does 
not affect the protein when already bound (Kohler and Cirillo, 2010). Intriguingly, five 
acetylation sites have been identified in the wings of the fork-head domain; three of them in 
W2 (K264, K267 and K270) where most of our newly observed FOXA1 mutations cluster. 
These observations lead to the hypothesis that FOXA1 mutations could alter EP300 
dependent acetylation of FOXA1 without affecting EP300 modulation of ER. While a 
rigorous evaluation of the role of EP300 in breast cancer and how FOXA1 mutations 
interfere with it goes beyond the scope of this study, FOXA1 mutations, its correlation with 
FOXA1 expression and lack of DNA methylation at its binding sites, and exclusivity with 
GATA3 mutations support these as events activating FOXA1 function and, thus, ER 
transcriptional program.
The PI3K/Akt pathway is among the most altered in cancer providing tumor cells with 
enhanced growth and survival capabilities. Integrating protein and phospho-protein data 
with gene expression and pathway activity signatures, we consistently identified increased 
Akt signaling in ILC versus IDC. Notably, E-cadherin loss has been associated with Akt 
activation and EGFR over-expression (Lau et al., 2011; Liu et al., 2013). Lack of E-cadherin 
expression, which characterizes almost all ILC tumors, may thus provide a favorable cellular 
context for Akt activation. Recently, PI3K and Akt inhibitors entered clinical trials for 
several cancer types including breast cancer. Here we showed that ILC has on average the 
highest levels of Akt activation, measured by phospho-Akt and PI3K/Akt signaling among 
all breast cancer subtypes (comparable to IDC Basal-like), making selective inhibition of 
this pathway in ILC a particularly attractive strategy.
Unbiased characterization of the ILC transcriptome showed a high degree of internal 
variability giving rise to three main subgroups: reactive-like, immune-related, and 
proliferative. While additional validation studies will clearly be required, we do observe 
increased expression of many druggable pathways/targets including increased levels of 
phospho-mTOR and phospho-MEK1 expression in the immunerelated subgroup as well as 
increased SMO and ERK pathway activity in the reactivelike subgroup. These results 
coupled with difference in clinical outcome suggests that these subgroups will be important 
for future studies focused on both the clinical and biological aspects of ILC.
Finally, we showed that mixed ILC/IDC tumors could be separated into two major groups 
based on their molecular resemblance to either ILC (ILC-like) or IDC (IDC-like). The 
ability to classify cancers with mixed phenotypes based on the underlying biology has 
implications for clinical practice as well as furthering our understanding of the etiology of 
such lesions. Indeed, ILC carcinomas often metastasize to body sites not colonized by IDCs 
(e.g. gastrointestinal (GI) tract and peritoneal surfaces). ILC are also typically of low 
histologic grade and with low to intermediate mitotic index, thus limiting their response to 
primary chemotherapy (Cristofanilli et al., 2005) and their ability to be detected on PET 
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scans. As such, clinicians must be aware of non-specific symptomatology and favor 
diagnostic approaches such as anatomical scanning (CT scan) for ILCs. Finally, the 
identification of ILC enriched molecular features may ultimately lead to the design of ILC-
targeted therapies. A more refined classification of mixed cancers as IDC-like or ILC-like 
will improve our understanding, detection and follow-up of the disease, and enable a more 
informed and targeted treatment selection.
This multi-platform study identified numerous molecular features discriminating between 
breast ILC and IDC, demonstrating different pathways underlying their pathogenesis, 
defining new ILC subtypes with different clinical outcomes, and pointing to previously 
unrecognized therapeutic possibilities. Importantly, we provided here a curated and 
integrated dataset for 817 breast tumors, including the largest collection to date of 
comprehensively profiled ILC. To facilitate the exploration of this dataset, we created a 
public web-service (http://cbio.mskcc.org/cancergenomics/tcga/brca_tcga) organizing all 
analyses and data used in this manuscript. We believe this resource will serve as a reference 
for many to further advance our understanding of human breast cancers.
Experimental procedures
Tumor and matched normal specimen were collected as previously described (Cancer 
Genome Atlas, 2012). In total 817 primary tumor samples were assayed by whole exome 
DNA sequencing, RNA sequencing, miRNA sequencing, SNP arrays, and DNA methylation 
arrays. A subset of 633 samples was assayed by reverse phase protein array (RPPA). 
Histological subtypes have been determined based on consensus by a pathology committee. 
Intrinsic breast cancer subtyping was performed on all 817 cases, using the PAM50 
classifier (Parker et al., 2009). Data generation and processing were performed as previously 
described (Cancer Genome Atlas Research, 2014).
Enrichment analyses for selected events were performed using Fisher’s exact tests and a 
binary representation of copy number alterations and mutations (1 is altered, 0 is wild-type).
DNA methylation of the CDH1 promoter was assessed at probes within a window 1500 bp 
upstream and downstream CDH1 transcription start site using both HM27 and HM450 data. 
Whole genome bisulfite sequencing was performed to characterize DNA methylation levels 
at 157 CpGs.
Distances between of FOXA1 mutations have been determined from the tertiary structure of 
FOXA3 fork-head domain (PDB ID: 1VTN). Predicted DNA interactions were derived by 
WebPDA (http://bioinfozen.uncc.edu/webpda). Differential expression analyses on RNA-
seq data were performed using the limmavoom package (Law et al., 2014).
Replication Based Normalized (RBN) RPPA data containing expression levels for 187 
protein and phosphorylated proteins for 633 samples were used for protein differential 
expression analysis. Differential pathway activity was assessed by t-test.
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ILC subtypes were determined using Consensus Cluster Plus Analysis (Wilkerson and 
Hayes, 2010) based on the 1000 most differentially expressed genes and a classifier was 
built using ClaNC (Dabney, 2006).
Detailed description of each analysis presented in this study can be found within the 
Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Comprehensive molecular profiles of 817 invasive breast tumors.
• Invasive lobular carcinoma (ILC) is a clinically and molecularly distinct disease.
• ILCs show CDH1 and PTEN loss, AKT activation, and mutations in TBX3 and 
FOXA1.
• Proliferation and immune-related gene expression signatures define 3 ILC 
subtypes.
• Genetic features classify mixed tumors into lobular-like and ductal-like 
subgroups.
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Figure 1. Molecular determinants of invasive lobular breast cancer
A) Histopathological breast cancer subtypes: invasive ductal (IDC), invasive lobular (ILC), 
mixed ductal/lobular (Mixed), and other-type (Other) carcinoma. PAM50 intrinsic subtypes 
are not equally distributed across breast cancer subtypes. B) Recurrently mutated genes 
(MutSigCV2) in ILC. C) Comparison of the alteration frequency for 153 recurrent genomic 
alterations in ILC versus IDC. D) Comparison of the alteration frequency for 153 recurrent 
genomic alterations in ILC LumA versus IDC LumA.
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Figure 2. E-cadherin loss in ILC
A) Mutations targeting the CDH1 gene target residues across the whole sequence and are 
mostly predicted to be truncating (red). B) Comparison of E-cadherin status between ILC 
and IDC reveals frequent hemizygous copy number losses at the CDH1 locus and 
downregulation of both mRNA [log2(RSEM)] and protein levels. See also Figure S2A–C. 
Average DNA methylation level of 6 probes at the CDH1 promoter shows no change in 
DNA methylation in both ILC and IDC samples. See also Figure S2D–I.
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Figure 3. Recurrent FOXA1 mutations cluster in the 3D space and correlate with high FOXA1 
activity
A) Recurrent FOXA1 mutations in 817 breast tumors cluster in the Fork-head DNA binding 
(FK) domain and in the C-terminus trans-activation (TA) domain. B) Secondary structure 
elements of the FK domain are not equally mutated. FOXA1 mutations cluster in the W2 
loop and rarely target residues interacting with the DNA. C) Residue-residue minimum 
distances for all residues in the FK domain using the 3D structure of FOXA3 FK domain 
(PDB ID: 1VTN). Frequently mutated residues I176 and D226 are close in the 3D space (but 
not in the sequence) to the residues in the W2 loop. See also Figure S3C. D) 3D structure of 
the FK domain. Mutations in the W2 loop, in I176, and in D226 form a mutational structural 
hotspot (MSH). E) 3D structure of FK domain bound to the DNA molecule shows mutated 
residues (red) are not those in contact with the DNA (light blue). F) Across all breast cancer 
subtypes (histopathology and PAM50), FOXA1 mutations are associated with FOXA1 high 
mRNA expression. FOXA1 mRNA expression is highly correlated with ER mRNA 
expression [log−2(RSEM)] and anti-correlated with DNA methylation at FOXA1 binding 
sites consistent with FOXA1 activity. DNA methylation of randomly selected probes was 
used as control.
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Figure 4. Akt signaling is highest in ILC tumors
A) Differential protein and phospho-protein analysis between ILC LumA and IDC LumA 
reveals significant lower levels of PTEN, and higher levels of Akt, phospho-Akt, EGFR, 
phospho-EGFR, phopsho-STAT3, and phospho-p70S6K in ILC LumA. B) A PI3K/Akt 
protein expression signature is significantly up-regulated in ILC tumors. See also Figure 
S4B–C. C) Mutation and copy number alterations in PIK3CA and PTEN D) PARADIGM 
identifies increased Akt activity in LumA ILC tumors. E) MEMo identified multiple 
mutually exclusive alterations in ILC converging on Akt signaling and associated with 
increased phospho-Akt and PI3K/Akt protein signature in these tumors. Hotspot are defined 
as follow: PIK3CA E542, E545, Q546, and H1047; ERBB2 L755, I767, V777; AKT1 E17; 
KRAS G12.
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Figure 5. ILC molecular subtypes
A) Three molecular subtype of lobular breast cancer were identified based on differential 
gene expression and show unique patterns highly expressed genes (n=1277, SAM FDR=0, 
upper panel), minor difference in tumor purity measured by ABSOLUTE, and differences in 
gene expression signatures measuring proliferation, CD68, Macrophage-associated CSF1, 
Macrophage–associated TH1, and T Cell Receptor Signaling (lower panel). Proliferation is 
highest in the proliferative (Pro) and immune-related (IR) subgroups; macrophage 
associated signaling is highest in immune-related tumors. B) Differences in protein 
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expression profiles as determined by RPPA analysis. The reactive-like (RL) subgroup shows 
a significant association (p<1E-4, Fisher’s Exact test) with the RPPA-defined Reactive 
subgroup of breast cancer. Differences in subgroup-specific patterns of protein expression 
(p<0.05, t-test) for individual proteins (upper panel) as well as for protein expression 
signatures (lower panel) were identified. The proliferative subgroup shows higher 
expression of the cell cycle and DNA damage response pathways and lower levels of Ras-
MAPK signaling (p<0.05). C) Subgroup-associated signaling features identified by 
PARADIGM. D) Reactive-like (n=55) tumors have significantly better disease specific 
(p=0.038, HR: 0.47, log-rank) and E) overall survival (p=0.022, HR=0.50) compared to 
proliferative (n=44) tumors in the METABRIC cohort. See also Figure S5.
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Figure 6. Molecular classification of mixed ductal/lobular carcinoma
A) Mixed ductal/lobular tumors present at the same time both a lobular and ductal 
component. B) We used three algorithmic approaches (ElasticNet, OncoSign, and ISOpure) 
to evaluate the resemblance of mixed tumors to either ILC (ILC-like) or IDC (IDC-like) 
based on molecular features. ILC-IDC scores are shown for all three approached at the top. 
See also Figure S6B–D. C) Genetic alterations enriched in ILC tumors are frequently found 
in ILC-like mixed cases (in particular CDH1 mutations), whereas those enriched in IDC are 
more frequent in IDC-like mixed cases. D) ILC-like mixed-cases are characterized by both 
low E-cadherin mRNA and protein level. See also Figure S6E.
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